Paper42100345
The role of pluripotency regulators in triple-negative breast cancer immune response.
López-Santana C and 2 others. Front Genet, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. The role of pluripotency regulators in triple-negative breast cancer immune response. Papers, record 42100345. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42100345
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References120
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23926105 | Loss of epigenetic Kruppel-like factor 4 histone deacetylase (KLF-4-HDAC)-mediated transcriptional suppression is crucial in increasing vascular endothelial growth factor (VEGF) expression in breast cancer. | J Biol Chem | 2013 | https://conductscience.org/library/papers/23926105 | PubMed |
| 2 | 16710719 | Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. | Cancer Immunol Immunother | 2007 | https://conductscience.org/library/papers/16710719 | PubMed |
| 3 | 38505617 | Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer. | Theranostics | 2024 | https://conductscience.org/library/papers/38505617 | PubMed |
| 4 | 24799675 | Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24799675 | PubMed |
| 5 | 35760778 | Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. | Nat Commun | 2022 | https://conductscience.org/library/papers/35760778 | PubMed |
| 6 | 30035158 | Targeting MYC for triple-negative breast cancer treatment. | Oncoscience | 2018 | https://conductscience.org/library/papers/30035158 | PubMed |
| 7 | 35814205 | Role of microRNA/lncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35814205 | PubMed |
| 8 | 29750424 | Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. | Int J Oncol | 2018 | https://conductscience.org/library/papers/29750424 | PubMed |
| 9 | 31616443 | WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. | Front Immunol | 2019 | https://conductscience.org/library/papers/31616443 | PubMed |
| 10 | 33256070 | Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33256070 | PubMed |
| 11 | 25827713 | Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. | Stem Cells | 2015 | https://conductscience.org/library/papers/25827713 | PubMed |
| 12 | 27539549 | The hedgehog pathway in triple-negative breast cancer. | Cancer Med | 2016 | https://conductscience.org/library/papers/27539549 | PubMed |
| 13 | 41069341 | Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies. | Front Oncol | 2025 | https://conductscience.org/library/papers/41069341 | PubMed |
| 14 | 23340294 | Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23340294 | PubMed |
| 15 | 39001543 | Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39001543 | PubMed |
| 16 | 31324052 | Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31324052 | PubMed |
| 17 | 38213533 | Targeting cancer stem cell plasticity in triple-negative breast cancer. | Explor Target Antitumor Ther | 2023 | https://conductscience.org/library/papers/38213533 | PubMed |
| 18 | 31921137 | Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights. | Front Immunol | 2019 | https://conductscience.org/library/papers/31921137 | PubMed |
| 19 | 26727947 | Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh. | Sci Rep | 2016 | https://conductscience.org/library/papers/26727947 | PubMed |
| 20 | 31379945 | Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype. | J Oncol | 2019 | https://conductscience.org/library/papers/31379945 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42630934 | B-cells in breast cancer: current insights and challenges. | Front Oncol | 2026 | https://conductscience.org/library/papers/42630934 | PubMed |
| 42495706 | NUPR1 in breast cancer: mechanisms and potential applications. | Front Physiol | 2026 | https://conductscience.org/library/papers/42495706 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| KLF4 | 9314 | PubTator's text mining | https://conductscience.org/library/genes/9314 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| NANOG | 79923 | PubTator's text mining | https://conductscience.org/library/genes/79923 | NCBI Gene |
| POU5F1 | 5460 | PubTator's text mining | https://conductscience.org/library/genes/5460 | NCBI Gene |
| SHH | 6469 | PubTator's text mining | https://conductscience.org/library/genes/6469 | NCBI Gene |
| SOX2 | 6657 | PubTator's text mining | https://conductscience.org/library/genes/6657 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42100345
GET https://conductscience.org/api/papers/v1/42100345/references?page=2